| 1 |
Mechanisms that determine plasma cell lifespan and the duration of humoral immunity
Ian J. Amanna, Mark K. Slifka · Immunological Reviews
ReviewOpen access |
15 Jun 2010 |
351 |
| 2 |
Contributions of humoral and cellular immunity to vaccine-induced protection in humans
Ian J. Amanna, Mark K. Slifka · Virology
Open access |
9 Jan 2011 |
270 |
| 3 |
Plasma cell survival in the absence of B cell memory
Erika Hammarlund, Archana Thomas, Ian J. Amanna et al. · Nature Communications
Open access |
20 Nov 2017 |
215 |
| 4 |
Role of Multivalency and Antigenic Threshold in Generating Protective Antibody Responses
Mark K. Slifka, Ian J. Amanna · Frontiers in Immunology
Open access |
May 2019 |
148 |
| 5 |
Heterogeneity and longevity of antibody memory to viruses and vaccines
Alice Antia, Hasan Ahmed, Andreas Handel et al. · PLoS Biology
Open access |
10 Aug 2018 |
147 |
| 6 |
Development of a new hydrogen peroxide–based vaccine platform
Ian J. Amanna, Hans Peter Raué, Mark K. Slifka · Nature Medicine
Open access |
27 May 2012 |
132 |
| 7 |
How advances in immunology provide insight into improving vaccine efficacy
Mark K. Slifka, Ian J. Amanna · Vaccine
Open access |
5 Apr 2014 |
130 |
| 8 |
Durability of Vaccine-Induced Immunity Against Tetanus and Diphtheria Toxins: A Cross-sectional Analysis
Erika Hammarlund, Archana Thomas, Elizabeth A. Poore et al. · Clinical Infectious Diseases
Open access |
21 Mar 2016 |
113 |
| 9 |
Optimization of Peptide-Based ELISA for Serological Diagnostics: A Retrospective Study of Human Monkeypox Infection
Melissa E. Dubois, Erika Hammarlund, Mark K. Slifka · Vector-Borne and Zoonotic Diseases
Open access |
4 Jan 2012 |
94 |
| 10 |
A Hydrogen Peroxide-Inactivated Virus Vaccine Elicits Humoral and Cellular Immunity and Protects against Lethal West Nile Virus Infection in Aged Mice
Amelia K. Pinto, Justin M. Richner, Elizabeth A. Poore et al. · Journal of Virology
Open access |
6 Dec 2012 |
75 |
| 11 |
Questions regarding the safety and duration of immunity following live yellow fever vaccination
Ian J. Amanna, Mark K. Slifka · Expert Review of Vaccines
Open access |
8 Jun 2016 |
65 |
| 12 |
Wanted, dead or alive: New viral vaccines
Ian J. Amanna, Mark K. Slifka · Antiviral Research
Open access |
5 Sep 2009 |
63 |
| 13 |
Current trends in West Nile virus vaccine development
Ian J. Amanna, Mark K. Slifka · Expert Review of Vaccines
Open access |
Apr 2014 |
59 |
| 14 |
Successful Vaccines
Ian J. Amanna, Mark K. Slifka · Current topics in microbiology and immunology
Book chapterOpen access |
2018 |
39 |
| 15 |
An observer blinded, randomized, placebo-controlled, phase I dose escalation trial to evaluate the safety and immunogenicity of an inactivated West Nile virus Vaccine, HydroVax-001, in healthy adults
Christopher W. Woods, Ana Maria Sanchez, Geeta Krishna Swamy et al. · Vaccine
Open access |
18 Jan 2019 |
35 |
| 16 |
Persistence of Neutralizing Antibody Responses Among Yellow Fever Virus 17D Vaccinees Living in a Nonendemic Setting
Bettie W. Kareko, Brian L. Booty, Chad Douglas Nix et al. · The Journal of Infectious Diseases
Open access |
15 Aug 2019 |
28 |
| 17 |
Development of a novel serological assay for the detection of mpox infection in vaccinated populations
Jennifer L. Yates, Danielle Hunt, Karen E. Kulas et al. · Journal of Medical Virology
Open access |
Oct 2023 |
27 |
| 18 |
Advanced oxidation technology for the development of a next-generation inactivated West Nile virus vaccine
Benjamin K. Quintel, Archana Thomas, Danae E. Poer DeRaad et al. · Vaccine
Open access |
31 Dec 2018 |
26 |
| 19 |
Pre-clinical development of a hydrogen peroxide-inactivated West Nile virus vaccine
Elizabeth A. Poore, Dawn K. Slifka, Hans-Peter Raué et al. · Vaccine
Open access |
3 Dec 2016 |
24 |
| 20 |
Balancing the Efficacy and Safety of Vaccines in the Elderly
Ian J. Amanna · Open Longevity Science
Open access |
Jun 2012 |
24 |
| 21 |
Vaccine-mediated protection against Campylobacter -associated enteric disease
Benjamin K. Quintel, Kamm Prongay, Anne D. Lewis et al. · Science Advances
Open access |
24 Jun 2020 |
23 |
| 22 |
Development of a next-generation chikungunya virus vaccine based on the HydroVax platform
Dawn K. Slifka, Hans-Peter Raué, Whitney C. Weber et al. · PLoS Pathogens
Open access |
5 Jul 2022 |
20 |
| 23 |
Antiviral Immune Response After Live Yellow Fever Vaccination of a Kidney Transplant Recipient Treated With IVIG
Mark K. Slifka, Erika Hammarlund, Matthew W. Lewis et al. · Transplantation
Open access |
7 May 2013 |
19 |
| 24 |
Campylobacter vaccination reduces diarrheal disease and infant growth stunting among rhesus macaques
Sara M. Hendrickson, Archana Thomas, Hans-Peter Raué et al. · Nature Communications
Open access |
26 Jun 2023 |
17 |
| 25 |
Reduced infant rhesus macaque growth rates due to environmental enteric dysfunction and association with histopathology in the large intestine
Sara M. Hendrickson, Archana Thomas, Kamm Prongay et al. · Nature Communications
Open access |
11 Jan 2022 |
14 |
| 26 |
A Management Accounting Framework
Gary Cokins · Journal of Corporate Accounting & Finance
|
Nov 2001 |
14 |
| 27 |
A Flow Cytometry-Based Assay for Quantifying Non-Plaque Forming Strains of Yellow Fever Virus
Erika Hammarlund, Ian J. Amanna, Melissa E. Dubois et al. · PLoS ONE
Open access |
19 Sep 2012 |
12 |
| 28 |
Development of a virulent O’nyong’nyong challenge model to determine heterologous protection mediated by a hydrogen peroxide-inactivated chikungunya virus vaccine
Whitney C. Weber, Zachary J. Streblow, Takeshi F. Andoh et al. · PLoS neglected tropical diseases
Open access |
17 Mar 2025 |
8 |
| 29 |
Development of a hydrogen peroxide-inactivated vaccine that protects against viscerotropic yellow fever in a non-human primate model
Ian J. Amanna, Archana Thomas, Flora Engelmann et al. · Cell Reports Medicine
Open access |
Jul 2024 |
8 |
| 30 |
Active Circulation of Corynebacterium ulcerans among Nonhuman Primates
Archana Thomas, Ariel M Slifka, Sara M. Hendrickson et al. · Microbiology Spectrum
Open access |
12 Jul 2022 |
8 |
| 31 |
Antibody-Mediated Protection against Respiratory Viral Infection
Melissa E. Dubois, Paul Yoshihara, Mark K. Slifka · Seminars in Respiratory and Critical Care Medicine
|
2005 |
5 |
| 32 |
Summary of human West Nile virus vaccine meeting, 2024: Investigating barriers to development
Randall J. Nett, Aaron C. Brault, Amy J. Lambert et al. · Vaccine
Open access |
5 Nov 2025 |
3 |
| 33 |
Lessons learned from successful implementation of tetanus and diphtheria vaccination programs
Mark K. Slifka, Archana Thomas, Lina Gao et al. · Clinical Microbiology Reviews
Open access |
15 Jul 2025 |
3 |
| 34 |
Analysis of COVID-19 Transmission: Low Risk of Presymptomatic Spread?
Mark K. Slifka, William B. Messer, Ian J. Amanna · Archives of Pathology & Laboratory Medicine
Open access |
5 Jun 2020 |
2 |
| 35 |
Dynamic Inventory Optimization and Cost Reduction Using Motif Knowledge Heterogeneous Dollmaker Graph Attention Network for Global Supply Chain Efficiency
Karri Sairamakrishna BuchiReddy, Lohith Sai Andra, Banze Ryan et al. · Research Square
PreprintOpen access |
19 Feb 2026 |
0 |
| 36 |
The Keys to Implementing Activity-Based Management
Mohan Nair · Journal of Corporate Accounting & Finance
|
Mar 2000 |
0 |
| 37 |
Correlates of Vaccine-Induced Immunity: Historical Perspectives and Future Challenges
Ian J. Amanna
Book chapter |
2012 |
0 |